Академический Документы
Профессиональный Документы
Культура Документы
T
he number of people with in animal and in vitro models to be tion leading to ischemia, which will
diabetes worldwide was esti- a result of hyperglycemia-induced promote nerve cell injury and death.
mated at 131 million in 2000; it metabolic abnormalities.911 One Hyperglycemia and oxidative stress
is projected to increase to 366 mil- of the more commonly described also contribute to the abnormal gly-
lion by 2030.1 Previous studies have mechanisms of action is the polyol cation of nerve cell proteins and the
indicated that diabetic patients have pathway.10 In the development of inappropriate activation of protein
up to a 25% lifetime risk of developing neuropathy, the hyperglycemic state kinase C, resulting in further nerve
a foot ulcer.2 The annual incidence of leads to an increase in action of the dysfunction and ischemia.
diabetic foot ulcers is ~ 3%, and the enzymes aldose reductase and sorbi- Neuropathy in diabetic patients
reported incidence in U.S. and U.K. tol dehydrogenase. This results in the is manifested in the motor, auto-
studies ranges as high as 10%.3 conversion of intracellular glucose to nomic, and sensory components
Once an ulcer has developed, sorbitol and fructose. of the nervous system.7 Damage
there is an increased risk of wound The accumulation of these sugar to the innervations of the intrinsic
progression that may ultimately lead products results in a decrease in the foot muscles leads to an imbalance
to amputation; diabetic ulceration between flexion and extension of
synthesis of nerve cell myoinositol,
has been shown to precede amputa- the affected foot. This produces
required for normal neuron con-
tion in up to 85% of cases.3 At least anatomic foot deformities that cre-
duction. Additionally, the chemical
40% of amputations in diabetic ate abnormal bony prominences
conversion of glucose results in a
patients can be prevented with a and pressure points, which gradu-
depletion of nicotinamide adenine
team approach to wound care.4 The ally cause skin breakdown and
purpose of this review is to describe dinucleotide phosphate stores, which
are necessary for the detoxification ulceration.
the causes of lower-extremity ulcer- Autonomic neuropathy leads to
ation in diabetic patients and to of reactive oxygen species and for
the synthesis of the vasodilator nitric a diminution in sweat and oil gland
identify common methods of classifi- functionality. As a result, the foot
cation and treatment to aid primary oxide. There is a resultant increase
loses its natural ability to moisturize
care providers in determining appro- in oxidative stress on the nerve cell
the overlying skin and becomes dry
priate treatment approaches for their and an increase in vasoconstric-
and increasingly susceptible to tears
patients. and the subsequent development of
In Brief
Pathogenesis of Ulceration infection.
Diabetic foot ulcers result from the The development of lower The loss of sensation as a part of
simultaneous action of multiple extremity ulcers is a well known peripheral neuropathy exacerbates
contributing causes.5,6 The major potential complication for the development of ulcerations. As
underlying causes are noted to be patients with diabetes. This arti- trauma occurs at the affected site,
peripheral neuropathy and ischemia cle reviews the common causes patients are often unable to detect
from peripheral vascular disease.7 of diabetic foot ulceration and the insult to their lower extremi-
discusses methods for assessment ties. As a result, many wounds go
Neuropathy and treatment to aid providers in unnoticed and progressively worsen
More than 60% of diabetic foot ulcers developing appropriate strategies as the affected area is continuously
are the result of underlying neuropa- for foot care in individuals with subjected to repetitive pressure and
thy.7,8 The development of neuropathy diabetes shear forces from ambulation and
in affected patients has been shown weight bearing.
Figure 1. Common foot deformities resulting from diabetes complications: A) claw toe deformity (increased pressure is placed
on the dorsal and plantar aspects of the deformity as indicated by the triple arrows); and B) Charcot arthropathy (the rocker-
bottom deformity leads to increased pressure on the plantar midfoot). Adapted from Ref. 13.
Vascular Disease Assessment of Diabetic Foot Ulcers factor to the development of foot
Peripheral arterial disease (PAD) is A task force of the Foot Care Interest ulceration. In the visual inspection
a contributing factor to the develop- Group of the American Diabetes of the foot, the evaluator should
ment of foot ulcers in up to 50% of Association (ADA) released a 2008 check between the toes for the
cases.12,13 It commonly affects the report that specifies recommended presence of ulceration or signs of
tibial and peroneal arteries of the components of foot examinations for infection. The presence of callus or
calf. Endothelial cell dysfunction and patients with diabetes.13 Providers nail abnormalities should be noted.
smooth cell abnormalities develop in should take a history that takes into Additionally, a temperature differ-
peripheral arteries as a consequence consideration previous ulceration or ence between feet is suggestive of
of the persistent hyperglycemic amputation. The history should also vascular disease.
state.9 There is a resultant decrease include any neuropathic symptoms The foot should also be examined
in endothelium-derived vasodilators or symptoms that are suggestive of for deformities. The imbalance in
leading to constriction. Further, the peripheral vascular disease. Further, the innervations of the foot muscles
hyperglycemia in diabetes is associ- providers should inquire about other from neuropathic damage can
ated with an increase in thromboxane complications of diabetes, including lead to the development of com-
A2, a vasoconstrictor and platelet vision impairment suggestive of retin- mon deformities seen in affected
aggregation agonist, which leads to an opathy and nephropathy, especially patients. Hyperextension of the
increased risk for plasma hypercoagu- dialysis or renal transplantation. metatarsal-phalangeal joint with
lability.14 There is also the potential Finally, patients should be questioned interphalangeal or distal phalangeal
for alterations in the vascular extra- regarding smoking because smok- joint flexion leads to hammer toe
cellular matrix leading to stenosis of ing is linked to the development of and claw toe deformities, respec-
the arterial lumen.14 Moreover, smok- neuropathic and vascular disease. A tively. The Charcot arthropathy is
ing, hypertension, and hyperlipidemia complete history will aid in assessing another commonly mentioned defor-
are other factors that are common in the risk for foot ulceration.13 mity found in some affected diabetic
diabetic patients and contribute to the In examining the foot, visual patients. It is the result of a com-
development of PAD.5 Cumulatively, inspection of the bare foot should bination of motor, autonomic, and
this leads to occlusive arterial disease be performed in a well-lit room. sensory neuropathies in which there
that results in ischemia in the lower The examination should include an is muscle and joint laxity that lead
extremity and an increased risk of assessment of the shoes; inappropri- to changes in the arches of the foot.
ulceration in diabetic patients. ate footwear can be a contributing Further, the autonomic denervation
wheelchairs, and crutches. There are changes and wound inspection antibiotic therapy or who need close
advantages and disadvantages to each should occur on a daily basis.26 monitoring for treatment response.28
modality, and factors such as overall If infection is suspected in the In the absence of serious signs,
wound condition, required frequency wound, the selection of appropriate patients can be treated with out-
for assessment, presence of infec- treatments should be based on the patient therapy and frequent
tion, and the likelihood for patient results of a wound culture. Tissue follow-up.30 Although a detailed
compliance should be considered in curettage from the base of the ulcer discussion of the range of antibi-
determining which modality would be after debridement will reveal more otic therapy is beyond the scope
most beneficial to the patient.24 accurate results than a superficial of this review, common classes of
The open diabetic foot ulcer wound swab.28In the case of deep agents used include cephalosporins,
may require debridement if necrotic tissue infections, specimens obtained fluoroquinolones, and penicillin/B-
or unhealthy tissue is present. The aseptically during surgery provide lactamase inhibitors. Information
debridement of the wound will optimalresults.28 about specificagents that have
include the removal of surround- Gram-positive cocci are typi- shown clinical effectiveness and sug-
ing callus and will aid in decreasing cally the most common pathogens gested treatment schemes based on
pressure points at callused sites on isolated. However, chronic or previ- infection severity has been published
the foot. Additionally, the removal of ously treated wounds often show elsewhere.25,28
unhealthy tissue can aid in removing polymicrobial growth, including The possibility of underlying
colonizing bacteria in the wound. It gram-negative rods or anaerobes. osteomyelitis should be considered
will also facilitate the collection of Pseudomonas, for example, is often with the presence of exposed bone
appropriate specimens for culture cultured from wounds that have been or bone that can be palpated with
soaked or treated with wet dress- a blunt probe. If osteomyelitis is
and permit examination for the
ings. Anaerobic bacteria are often diagnosed, the patient may undergo
involvement of deep tissues in the
cultured from ulcers with ischemic surgical excision of the affected bone
ulceration.25
necrosis or deep tissue involvement. or an extensive course of antibiotic
The selection of wound dressings
Antibiotic-resistant organisms such therapy.5
is also an important component of
as methicillin-resistant staphylo- Consideration is also given to
diabetic wound care management.
coccus aureus are frequently found the presence of underlying isch-
There are a number of available
in patients previously treated with emia because an adequate arterial
dressing types to consider in the
antibiotic therapy or patientswith a blood supply is necessary to facili-
course of wound care. Although
recent history of hospitalization or tate wound healing and to resolve
there is a dearth of published trials residence in a long-term care facility. underlying infections. Patients with
to support the use of one type of The selection of appropriate evidence of decreased distal blood
dressing compared to another,26 the antimicrobial therapy, including flow or ulceration that does not
characteristics of specific dressing the agent, route of administration, progress toward healing with appro-
types can prove beneficial depending and need for inpatientor outpatient priate therapy should be referred to
on the characteristics of the indi- treatment will be determined in a vascular specialist. Upon deter-
vidual wound. Saline-soaked gauze part by the severity of the infection. mination of the patients anatomy
dressings, for example, are inexpen- Clinical signs of purulent drainage, and a vascular route amenable to
sive, well tolerated, and contribute to inflammatory signs of increased restoration, the patient may undergo
an atraumatic, moist wound environ- warmth, erythema, pain and indura- arterial revascularization.
ment. Foam and alginate dressings tion, or systemic signs such as fever Surgical bypass is a common
are highly absorbent and can aid in or leukocytosis should be consid- method of treatment for ischemic
decreasing the risk for maceration ered. Patients with systemic signs of limbs, and favorable long-term
in wounds with heavy exudates. A severe infection should be admitted results have been reported.31 Up
complete discussion of the various for supportive care and intravenous to a 90% 10-year limb-salvage rate
classes of wound dressings is beyond antibiotic therapy; additionally, a has been demonstrated with surgi-
the scope of this review; however, an surgical evaluation is warranted to cal bypass procedures of the lower
ideal dressing should contribute to evaluate for a deep occult infection.29 extremity.32 In cases in which there
a moist wound environment, absorb Inpatient care is also suggested for are multiple levels of occlusion,
excessive exudates, and not increase patients who are not able to provide revascularization at each point is
the risk for infections.27 Dressing proper self-care or comply with necessary to restore arterial blood
flow and increase the chance for limb use of granulocyte colony stimulat- adequately powered randomized
salvage.31 Transluminal angioplasty ing factors (G-CSF). HBOT is the trial.39
of the iliac arteries in conjunction delivery of oxygen to patients at However, the Center for Medicare
with surgical bypass in the distal higher than normal atmospheric & Medicaid Services has approved
extremity may be implemented, and
pressures. This results in an increase reimbursement of HBOT for 14
efficacy has been demonstrated in
diabetic patients.33 in the concentration of oxygen in the conditions, including diabetic
A number of adjunctive wound blood and an increase in the dif- ulcers. Diabetic wounds that meet
care treatments are under investi- fusion capacity to the tissues. The the appropriate criteria are classi-
gation and in practice for treating partial pressure of oxygen in the fied as WagnerGrade 3 wounds that
diabetic foot ulcers. The use of tissues is increased, which stimulates
have failed to resolve after a 30-day
human skin equivalents has been neovascularization and fibroblast
shown to promote wound healing course of standard treatment.
replication and increases phagocyto-
in diabetic ulcers via the action The use of G-CSF is another new
sis and leukocyte-mediated killing of
of cytokines and dermal matrix adjunctive therapy under inves-
components that stimulate tissue bacterial pathogens in the wound.
tigation. G-CSF has been found
growth and wound closure.34,35 A Presently, there are conflicting
to enhance the activity of neutro-
recombinant platelet-derived growth data regarding the efficacy of this
factor is also currently in use and therapy. Although small random- phils in diabetic patients.40 A small
has been shown to stimulate wound izedstudies have demonstrated an number of studies have investigated
healing.36 However, the present data improvement in the rate of wound the use of G-CSF as an adjunctive
for most of these modalities are not healing and a decrease in the num- therapy. A meta-analysis of these
considered sufficient for routine studies41 revealed that, although the
ber of amputations,37,38 other studies
implementation in the treatment of
contest these data. The quality of use of G-CSF did not significantly
diabetic wounds.25
Two of the more popular adjunc- the studies to date has been poor, accelerate the resolution of infec-
tive therapies in use are hyperbaric and their findings have not been tion in diabetic wounds, there was a
oxygen therapy (HBOT) and the confirmed in a large, blinded, and decreased likelihood of amputation
Table 3. Risk Classification System of the Task Force of the Foot Care Interest Group of the ADA
Risk Category Definition Treatment Recommendations Suggested Follow-up
0 No LOPS, no PAD, no Consider patient education on Annually (by generalist and/or specialist)
deformity foot care, including information
on appropriate footwear.
1 LOPS deformity Consider prescriptive or accom- Every 36 months (by generalist or
modative footwear. specialist)
Consider prophylactic surgery
if deformity is not able to be
safely accommodated in shoes.
Continue patient education.
2 PAD LOPS Consider the use of accommoda- Every 23 months (by specialist)
tive footwear.
Consider a vascular consultation
for combined follow-up.
3 History of ulcer or Consider patient education on Every 12 months (by specialist)
amputation foot care.
Consider vascular consultation
for combined follow-up if PAD
present.
LOPS, loss of protective sensation; PAD, peripheral arterial disease. Adapted from Ref. 13.
and the need for other surgical thera- If ulcers are present, the treat- esis of diabetic neuropathy. Curr Opin Neurol
5:553563, 1999
pies in treated wounds. ment strategy should include 11
Simmons Z, Feldman E: Update on
offloading, debridement, and diabetic neuropathy. Curr Opin Neurol
Prevention appropriate dressings. Further, the 15:595603, 2002
Early detection of potential risk fac- presence of infections should be 12
Huijberts MS, Schaper NC, Schalkwijk
tors for ulceration can decrease the determined by clinical findings and CG: Advanced glycation end products and
diabetic foot disease. Diabetes Metab Res Rev
frequency of wound development. It appropriate wound cultures and 24 (Suppl. 1):S19S24, 2008
is recommended that all patients with treated based on the culture results. 13
Boulton AJ, Armstrong DG, Albert
diabetes undergo foot examinations at If evidence for ischemia is present, SF, Frykberg RG, Hellman R, Kirkman
least annually to determine predis- MS, Lavery LA, LeMaster JW, Mills JL
revascularization may be indicated Sr, Mueller MJ, Sheehan P, Wukich DK:
posing conditions to ulceration.13 to restore arterial blood flow and Comprehensive foot examination and risk
Patients should be educated regarding assessment. Diabetes Care 31:16791685, 2008
increase the chance for limb sal-
the importance of maintaining good vage. There are adjunctive therapies
14
Paraskevas KI, Baker DM, Pompella
A, Mikhailidis DP: Does diabetes mellitus
glycemic control, wearing appropriate available that can also contribute play a role in restenosis and patency rates
footwear, avoiding trauma, and per- to the overall healing process of the following lower extremity peripheral arterial
revascularization? A critical overview. Ann
forming frequent self-examinations.25 wounds in affected patients. Vasc Surg 22:481491, 2008
A risk classification scheme By conducting a periodic foot 15
Khan NA, Rahim SA, Anand SS, Simel
has been created in the report of survey in diabetic patients and incor- DL, Panju A: Does the clinical examination
the task force of the Foot Care predict lower extremity peripheral arterial
porating the appropriate basic and disease? JAMA 295:536546, 2006
Interest Group of the ADA13 that is specialized care as warranted, the 16
American Diabetes Association:
reportedly designed to make basic risk of ulceration and its associated Peripheral arterial disease in people with
recommendations regarding the diabetes. Diabetes Care 26:33333341, 2003
morbidities can be reduced.
need for specialist referral and the 17
Armstrong DG, Lavery LA, Vela SA,
Quebedeaux TL, Fleischli JG: Choosing a
frequency of follow-up by primary References practical screening instrument to identify
providers and specialists (Table 3). 1
Wild S, Roglic G, Green A, Sicree R, patients at risk for diabetic foot ulceration.
King H: Global prevalence of diabetes: esti- Arch Intern Med 158:289292, 1998
Patients in the lowest risk category mates for the year 2000 and projections for 18
Frykberg RG, Armstrong DG, Giurini
are recommended to receive educa- 2030. Diabetes Care 27:10471053, 2004 J, Edwards A, Kravette M, Kravitz S, Ross
tion on general foot care and annual 2
Singh N, Armstrong DG, Lipsky BA: C, Stavosky J, Stuck R, Vanore J: Diabetic
follow-up. Increasing risk catego- Preventing foot ulcers in patients with diabe- foot disorders: a clinical practice guideline.
tes. JAMA 293:217228, 2005 J Foot Ankle Surg 39 (5 Suppl.):S1S60, 2000
ries require more components of American Diabetes Association:
3
Reiber GE, Vileikyte L, Boyko EJ, del 19
care and are more likely to benefit Aguila M, Smith DG, Lavery LA, Boulton Consensus development conference on
from specialist care and follow- AJ: Causal pathways for incident lower diabetic foot wound care: 78 April 1999,
extremity ulcers in patients with diabetes Boston, Massachusetts. Diabetes Care
up. A recommended frequency of from two settings. Diabetes Care 22:157162, 22:13541360, 1999
follow-up for each risk category is 1999 20
Wagner FW Jr: The diabetic foot.
also included in the table; follow-
4
Lavery LA, Armstrong DG, Vela SA, Orthopedics 10:163172, 1987
Quebedeaux TL, Fleischli JG: Practical
up increases in frequency with an criteria for screening patients at high risk
21
Frykberg RG: Diabetic foot ulcers:
for diabetic foot ulceration. Arch Intern Med pathogenesis and management. Am Fam Phys
increase in risk category. 66:16551662, 2002
158:157162, 1998
5
Armstrong DG, Lavery LA: Diabetic
22
Oyibo SO, Jude EB, Tarawneh I,
Conclusion Nguyen HC, Harkless LB, Boulton AJ:
foot ulcers: prevention, diagnosis and clas-
Patients with diabetes are at an sification. Am Fam Phys 57:6:13251332, A comparison of two diabetic foot ulcer
13371338, 1998 classification systems: the Wagner and the
increased risk for developing foot University of Texas wound classification
ulcerations. The consequences of 6
Kelkar P: Diabetic neuropathy. Sem systems. Diabetes Care 24:8488, 2001
Neurol 25:168173, 2006
persistent and poorly controlled 23
Armstrong DG, Lavery LA, Nixon BP,
7
Bowering CK: Diabetic foot ulcers: Boulton AJ: Its not what you put on, but
hyperglycemia lead to neuropathic pathophysiology, assessment, and therapy. what you take off: techniques for debriding
and vascular abnormalities that Can Fam Phys 47:10071016, 2001 and off-loading the diabetic foot wound. Clin
cause foot deformities and ulceration. 8
Dyck PJ, Davies JL, Wilson DM, Service Infect Dis 39:S92S99, 2004
FJ, Melton LJ III, Obrien PC: Risk factors
The feet of diabetic patients should for severity of diabetic polyneuropathy.
24
Armstrong DG, Nguyen HC, Lavery
LA, Van Schie CH, Boulton AJ, Harkless LB:
be examined at least annually to Diabetes Care 22:14791486, 1999 Off-loading the diabetic foot wound. Diabetes
determine predisposing conditions to 9
Zochodone DW: Diabetic polyneuropa- Care 24:10191022, 2001
thy: an update. Curr Opin Neurol 21:527533,
ulceration. Treatment plans should be 2008
25
Lipsky BA, Berendt AR, Deery HG,
Embil JM, Joseph WS, Karchmer AW,
based on examination findings and 10
Feldman EL, Russell JW, Sullivan KA, LeFrock JL, Lew DP, Mader JT, Norden C,
the individual risk for ulceration. Golovoy D: New insights into the pathogen- Tan JS: Diagnosis and treatment of diabetic